Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Merck
Citi
Daiichi Sankyo
AstraZeneca

Generated: September 24, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,338,489

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,338,489 protect, and when does it expire?

Patent 8,338,489 protects HEMANGEOL and is included in one NDA.

This patent has forty-six patent family members in thirty countries.

Summary for Patent: 8,338,489
Title:Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract: The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s): Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Beno t (Bordeaux, FR)
Assignee: Universite Victor Segalen--Bordeaux 2 (Bordeaux Cedex, FR)
Application Number:12/599,266
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,338,489

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes   Try a Free Trial   Try a Free Trial METHOD TO TREAT HEMANGIOMA.   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,338,489

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07291273Oct 19, 2007
PCT Information
PCT FiledOctober 16, 2008PCT Application Number:PCT/IB2008/002746
PCT Publication Date:April 23, 2009PCT Publication Number: WO2009/050567

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
Julphar
Chubb
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.